Omri Amirav‑Drory, Ph.D., is a biotech entrepreneur turned investor who serves as a General Partner at NFX Bio, splitting his time between Israel and the Bay Area. Before joining NFX in 2020, he founded and led Genome Compiler (a platform for genetic engineering) through its acquisition by Twist Bioscience, later heading corporate development there. He also co-founded Tech.Bio, supporting cutting-edge ventures like Mammoth Biosciences and C2i Genomics. With a Ph.D. from Tel Aviv University and postdoctoral work at Stanford, Omri champions the “scientist-CEO” model—investing in founders who bridge deep scientific expertise and entrepreneurial drive to build transformative tech-bio companies.